Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation

Eilat Hanan, Beka Solomon*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

In vitro aggregation of β-amyloid peptide induced by incubating the peptide for 3 h at 37°C, was investigated via immunocomplexation with a panel of monoclonal antibodies raised against various β-amyloid fragments. Some of these monoclonal antibodies prevented the formation of β-amyloid and this effect may be related to the localization of the antibody binding sites. Monoclonal antibodies 6C6 and 10D5, and AMY-33, which recognize epitopes spanning the amino acid residues 1-28 of β-amyloid peptide, inhibited its aggregation by 40%-90% when compared with aggregation occurring in the absence of the respective antibodies. The antibodies, 2H3 and 1C2, directed to the regions comprising peptides 1-12 and 13-28, respectively, had a considerably low effect. Identifying the "aggregating epitopes" as sequences that are related to the sites where protein aggregation is initiated and preparing monoclonal antibodies against these regions may facilitate the understanding and prevention of protein aggregation processes. This study may provide a factual basis for using monoclonal antibodies to prevent the β-amyloid formation that is associated with Alzheimer's disease.

Original languageEnglish
Pages (from-to)130-133
Number of pages4
JournalAmyloid
Volume3
Issue number2
DOIs
StatePublished - 1996

Keywords

  • Aggregation
  • Monoclonal antibodies
  • Protection
  • β-amyloid

Fingerprint

Dive into the research topics of 'Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation'. Together they form a unique fingerprint.

Cite this